X4 Pharma’s Success After Cutbacks Will Comfort Hard-Hit Biotechs
Cost-Cutting And Focus On Lead Asset Pays Off
X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.
